References
- Hernandez JS. Cost-effectiveness of laboratory testing. Arch Pathol Lab Med 2003;127:440–5.
- Fraser CG, Hyltoft Petersen P. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321–3.
- Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. JAMA 1995;274: 645–51.
- Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JHP, Bossuyl PMM. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061–6.
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, deVet HCW, Lijmer JG. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003;49:7–18.
- Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993;13:313–21.
- Parvin CA, Lo SF, Deuser SM, Weaver LG, Lewis LM, Scott MG. Impact of point-of-care testing on patients' length of stay in a large emergency department. Clin Chem 1996;42:711–7.
- Despotis GJ, Hoist JH, Goodnough LT. Monitoring of hemostasis in cardiac surgical patients: impact of point- of-care testing on blood loss and transfusion outcomes. Clin Chem 1997;43:1684–96.
- The Lewin Group, Inc. The value of laboratory screening and diagnostic tests for prevention and health care improvement. September 2009. http://www.labresultsforlife.org/briefing/Lewin_ACLA_Value_of_Lab_Sx_Dx_Report.pdf (accessed 10-04-14).
- United States Preventive Services Task Force Website. http://www.ahrq.gov/clinic/uspstf/grades.htm#post (accessed 10-04-14).
- National Health Service in the United Kingdom http://www.nice.org.uk. (accessed 10-04-14).
- US Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Int Med 2009;151:716–26.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, . PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–9.
- Esserman L, Shich Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302: 1685–92.
- Nass SJ, Moses HL. Methods and process needed for clinical adoption and evaluation of biomarker-based diagnostics (Chapter 4). Nass SJ, Moses HL. Cancer Biomarkers. National Academies Press, Washington, D.C., 2007. 114–34.
- Center for Medicare and Medicare Services. Decision Memorandum for Pharmacogenomic Testing to Predict Warfarin Responsiveness. August 3, 2009. Available from: www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=224 (accessed 10-04-14).
- Agency for Healthcare Research and Quality. Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism. June 2009. Available from: http://www.ahrq.gov/clinic/tp/fvltp.htm (accessed 10-04-14).
- Mutch DG. Ovarian cancer: to screen or not to screen. Obstet Gynecol 2009;113:772–4.
- Dhruva SS, Phurrough SE, Salive ME, Redberg RF. CMS's landmark decision on CT colonography – examining the relevant data. N Eng J Med 2009;360:2699–701.
- Price CP, Bossuyt PMM, Bruns DE. Principles of laboratory medicine (Chapter 13). Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Saunders, St. Louis, MO, 2006. p. 323–52.
- Tufts-New England Medical Center Cost-Effectiveness Registry http://www.research.tufts-nemc.org/cear/default.aspx (accessed 10-04-14).
- Russell LB. Preventing chronic disease: an important investment, but don't count on cost savings. Health Affairs 2009;28:42–5.
- Measuring Effectiveness and cost effectiveness: the QALY. National Institute for Health and Clinical Excellence Website. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. (accessed 10-04-14).
- Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008;28:66–89.
- Byme MM, O'Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005;25:655–66.
- Nass SJ, Moses HL. Economic Impact of Biomarkers (Appendix). Nass SJ, Moses HL, Cancer Biomarkers. National Academies Press, Washington, D.C., 2007. 194–203.
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322–38.
- Brouwer WBF, Niessen LW, Postma MJ, Rutten FFH. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331:446–8.
- Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996;276: 285–92.
- Pharmacologic management of heart failure and left ventricular systolic dysfunction. Effect in female, black, and diabetic patients, and cost-effectiveness summary. Evidence report/technology assessment: Number 82. AHRQ website. September 2003. Available from: http://www.ahrq.gov/clinic/epcsums/hrtfailsum.htm (accessed 10-04-14).
- Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:1019–26.
- National Institute for Health and Clinical Excellence (May 2009) Coeliac disease: Recognition and assessment of coeliac disease. CG86. London: National Institute for Health and Clinical Excellence. http://guidance.nice.org.uk/CG86/Guidance/pdf/English (accessed 10-04-14).
- Rubenstein J H, Inadomi J M, Vakil, N. The cost- effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma., Aliment Pharmacol Ther 2005;222):135–46.